The contribution of ␤-subunits to agonist efficacy in nicotinic receptors is incompletely understood. Results: Two nicotinic agonists displayed opposing efficacy profiles at receptors containing ␤2-or ␤4-subunits and maximal efficacy was determined by both ligand-binding and transmembrane ␤-subunit domains. Conclusion: The ␤-subunit is an important determinant of agonist efficacy. Significance: These findings provide support to structure-guided nicotinic receptor drug design.
Deciphering which specific agonist-receptor interactions affect efficacy levels is of high importance, because this will ultimately aid in designing selective drugs. The novel compound NS3861 and cytisine are agonists of nicotinic acetylcholine receptors (nAChRs) and both bind with high affinity to heteromeric ␣3␤4 and ␣4␤2 nAChRs. However, initial data revealed that the activation patterns of the two compounds show very distinct maximal efficacy readouts at various heteromeric nAChRs. To investigate the molecular determinants behind these observations, we performed in-depth patch clamp electrophysiological measurements of efficacy levels at heteromeric combinations of ␣3-and ␣4-, with ␤2-and ␤4-subunits, and various chimeric constructs thereof. Compared with cytisine, which selectively activates receptors containing ␤4-but not ␤2-subunits, NS3861 displays the opposite ␤-subunit preference and a complete lack of activation at ␣4-containing receptors. The maximal efficacy of NS3861 appeared solely dependent on the nature of the ligand-binding domain, whereas efficacy of cytisine was additionally affected by the nature of the ␤-subunit transmembrane domain. Molecular docking to nAChR subtype homology models suggests agonist specific interactions to two different residues on the complementary subunits as responsible for the ␤-subunit preference of both compounds. Furthermore, a principal subunit serine to threonine substitution may explain the lack of NS3861 activation at ␣4-containing receptors. In conclusion, our results are consistent with a hypothesis where agonist interactions with the principal subunit (␣) primarily determine binding affinity, whereas interactions with key amino acids at the complementary subunit (␤) affect agonist efficacy.
Activation of the neuronal nicotinic acetylcholine receptors (nAChRs)
3 is known to involve agonist binding in a site containing a set of highly conserved aromatic amino acid residues in the extracellular ligand-binding domain (LBD) (1) . In heteromeric neuronal nAChRs, this agonist binding site has been shown to be located in the interface between an ␣-and a ␤-subunit, described as the principal and complementary binding site components, respectively (2) . Consistent with these findings, functional studies have identified segments of the LBD of both ␣-and ␤-subunits as important determinants of agonist affinity (3, 4) . A significant part of the binding site is made up by the flexible C-loop that changes spatial location upon agonist binding (5) . This movement is subsequently translated into the pore opening by a not yet fully elucidated mechanism thought to involve rigid body rotation of the inner ␤-sheets, movements of loops in the interface between the LBD and the transmembrane domain (TMD), and a tilt of helix M2 (6) .
Agonists can display strong subtype selectivity, primarily in terms of efficacy, for heteromeric neuronal nAChRs containing particular ␣-or ␤-subunits (7, 8) , despite a very high sequence identity of the residues involved in agonist binding (9) . By analogy to the findings that agonist efficacy in glutamate receptors appears tightly linked to domain closure (10), C-loop closure has been suggested to be directly coupled to agonist efficacy in Cys-loop receptors (11) (12) (13) . However, in a recent study, it was demonstrated that a structurally related series of agonists with similar binding affinities but divergent efficacies all resulted in similar C-loop closure in co-crystallization experiments with acetylcholine-binding protein (AChBP) (14) . Hence, it appears that neither the binding determinants nor the degree of C-loop closure are sufficient to explain how efficiently an agonist gates a receptor. * This work was supported in part by grants from the Drug Research Acad-Despite having a large range of efficacies, the above mentioned series of partial agonists all contained the same core scaffold, which explains the similar binding affinities (14) . The major differences were observed in the interactions with the complementary subunit. Based on this, it was hypothesized that agonist efficacy is dependent on the strength with which the agonist can mediate interactions between the principal and complementary subunits. From the current knowledge it is likely that this inter-subunit interaction is an integral first step in triggering the movements or stabilizing the conformation that eventually lead to channel gating, however, it also prompts new questions. The first question is whether the principal subunit only delivers the framework to which an agonist binds, whereas determinants important for ligand efficacy are located on the complementary subunit? Furthermore, irrespective of the exact mechanism, translation of binding into ion-channel gating involves transmission of conformational changes in the LBD to the pore-forming TMD. The next question is then, whether the LBD fully determines agonist efficacy and the TMD consequently acts purely as a mechanical channel-gating switch, i.e. would any TMD that interlinks well with a given LBD result in similar efficacy levels of specific agonists?
As part of a drug discovery program, novel nAChR agonists of various selectivity profiles were designed. One such agonist, NS3861, was found to selectively activate ␣3-but not ␣4-containing nAChRs and it displays higher efficacy at the ␣3␤2 receptor compared with the ␣3␤4 receptor (present report). To the best of our knowledge, such a selectivity pattern has not previously been reported. Interestingly, this selectivity profile reciprocates that of the nAChR agonist cytisine, which is known to selectively activate ␤4-but not ␤2-containing nAChRs (8, 15) . These two compounds were therefore used as pharmacological tools to explore the relative contributions to maximum agonist efficacy of the principal (␣) and complementary (␤) subunits as well as the LBDs versus the TMDs. The studies entailed patch clamp electrophysiological measurements of heteromeric combinations of ␣3-and ␣4-with ␤2-and ␤4-subunits, and various chimeric constructs thereof. Receptor homology models and molecular docking were used to interpret the experimental data in terms of agonist binding modes and interactions to the binding site residues of the principal and complementary subunits.
In essence, we found the identity of the ␣-subunit to contribute to agonist efficacy in an "either/or" fashion. However, the determinants responsible for "fine tuning" agonist efficacy were particularly associated with the ␤-subunit LBD, although the ␤-subunit TMD was also observed to have some impact. Our findings from the molecular docking approach show that the observed subunit selectivities of NS3861 and cytisine can be attributed to a few residues in the binding sites that differ between ␣3-and ␣4-as well as ␤2-and ␤4-subunits.
EXPERIMENTAL PROCEDURES
Materials-(ϩ/Ϫ)-NS3861 was synthesized at NeuroSearch A/S. (Ϫ)-Cytisine (C2899), (Ϫ)-nicotine (N5260), acetylcholine (ACh) (A9101), and dihydro-␤-erythroidine hydrobromide (D149) were purchased from Sigma. All other chemicals were purchased from Sigma or Merck and were analytical grade. Molecular biology kits were from Qiagen (QIAquick columns, Maxiprep DNA, and Gel Extraction kits Molecular Biology-Cloning of the human nAChRs ␣3-, ␣4-, ␤2-, and ␤4-subunits was as described previously (16) . nAChR ␣-subunits and ␣-chimeras were in the pNS3n vector, whereas nAChR ␤-subunits and ␤-chimeras were in the pNS3z vector. pNS3n and pNS3z are custom designed vectors derived from pcDNA3 (Invitrogen) where "n" and "z" denotes selection using the NeoR or ZeoR genes, respectively. Both vectors use the CMV promoter to drive expression of the insert in mammalian cells. To generate ␣3/␣4-, ␣4/␣3-, ␤2/␤4-, and ␤4/␤2-chimeras a unique SalI restriction site was introduced close to the beginning of TM1 in each subunit by site-directed mutagenesis as described by Slilaty et al. (17) . Briefly, uracilated plasmids containing nAChR subunits were isolated from E. coli strain RZ1032, linearized with NruI, and used as template in mutagenesis reactions using a mutagenesis oligo, a closing oligo, T7 DNA polymerase, and T4 DNA ligase. Sequences of the mutagenesis oligonucleotides were: ␣3-SalI, CTCACTGT-ACATCCGTCGACTGCCCTTGTTCTACAC; ␣4-SalI, GCC-TTCGTCATCCGTCGACTGCCGCTCTTCTACAC; ␤2-SalI, GACTTCA-TCATTCGTCGACGGCCGCTCTTCTACAC; and ␤4-SalI, GACTTCATCATCCGTCGACGGCCTCTGTT-CTACAC. Correct introduction of SalI sites were verified by restriction enzyme digestion and further sequencing. Chimeric nAChRs were made by restriction digestion of the plasmids with SalI and NotI (polylinker site), gel electrophoresis purification of fragments, and re-ligation of relevant nAChR combinations. The resulting chimeric constructs were verified by restriction enzyme digestion and sequencing. To obtain an ␣4-subunit with a Thr 183 to Ser mutation as well as a ␤2-subunit with Val 136 to Ile and Phe 144 to Leu mutations, ␣4-and ␤2-LBDs, including the mutations, were purchased from GenScript and ligated with the respective TMDs using the SalI site.
Cell Culture and Transfection-HEK293 cells were propagated at 37°C in culture flasks in a humidified atmosphere containing 5% CO 2 . The growth medium consisted of DMEM supplemented with 10% FBS. For generation of clones stably expressing ␣3␤2, ␣3␤4, ␣4␤2, and ␣4␤4 nAChRs, HEK293 cells were seeded in T12.5 culture flasks, cultured to 50 -70% con-fluence, and transfected with a total of 1 g of expression plasmids using Lipofectamine Plus TM according to the manufacturer's protocol. Twenty-four hours post-transfection, the cells were detached using trypsin/EDTA and seeded in T75 culture flasks with a tear-off lid. To select stably expressing cells the culture medium was supplemented with 0.5 mg/ml of G418 and 0.125 mg/ml of Zeocin. Following selection, single clones were picked and propagated in selection media until sufficient cells for freezing were available. Thereafter the cells were propagated in regular culture media.
GH4Cl cells were cultured in tissue culture flasks at 37°C in a humidified atmosphere containing 5% CO 2 . The culture medium consisted of Ham's F-10 medium supplemented with 15% horse serum and 2.5% FBS. On the day before transfection, cells were seeded in 35-mm Petri dishes containing poly-D-lysine-coated round glass coverslips (Ø 3.5 mm, custom made at VWR International). The GH4Cl cells were then transfected using Lipofectamine Plus TM according to manufacturer's protocol. Each Petri dish was transfected with a mixture of plasmids containing cDNAs coding for relevant nAChRs and green fluorescent protein (Clontech); the latter to identify transfected cells in the patch clamp set-up. After transfection, the culture medium was supplemented with 50 mM KCl, as elevated K ϩ has previously been shown to facilitate expression of nAChRs in the GH4Cl cell line (18) .
Xenopus laevis oocyte preparation and electrophysiological experiments were performed as described previously (19) . Briefly, to obtain isolated oocytes lobes from ovaries of female adult X. laevis were removed and defolliculated using collagenase. Oocytes were injected with a total of ϳ25 ng of cRNA encoding human wild-type or concatenated subunits and incubated for 2-7 days at 15-18°C in modified Barth's solution (90 mM NaCl, 1.0 mM KCl, 0.66 mM NaNO 3 , 2.4 mM NaHCO 3 , 10 mM HEPES, 2.5 mM sodium pyruvate, 0.74 mM CaCl 2 , 0.82 mM MgCl 2 , 100 g/ml of gentamycin, and pH adjusted to 7.5).
Radioligand Binding Experiments-HEK293 cells stably expressing human ␣3␤2, ␣3␤4, ␣4␤2, and ␣4␤4 receptors were harvested, washed once with 50 mM Tris-HCl (pH 7.4), and stored at Ϫ80°C until the day of experiment. Thawed membrane pellets were re-suspended in 15 ml of ice-cold Tris-HCl buffer and centrifuged for 10 min (27,000 ϫ g) at 4°C. The final pellets were re-suspended in Tris-HCl buffer and used for binding experiments. The conditions for receptor binding assays were as described previously for [ 3 H]epibatidine binding to rat brain (20 Table 3 .
Patch Clamp Electrophysiology-Electrophysiological measurements in GH4Cl cells were performed in voltage clamp using conventional whole cell patch clamp techniques. All data were obtained with an EPC-9 amplifier (HEKA). The holding potential was Ϫ60 mV in all experiments. Coverslips with cells were placed in a diamond-shaped polycarbonate recording chamber (Warner Instruments) fixed at the stage of an inverted microscope (Olympus). Throughout the experiment, the cells were perfused with extracellular buffer (140 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES, pH adjusted to 7.4 using NaOH). Micropipettes were made from borosilicate capillary tubes by means of a horizontal micropipette puller (Zeitz Instruments). The pipettes were filled with intracellular buffer (120 mM potassium gluconate, 6 mM KCl, 5 mM NaCl, 2 mM MgCl 2 , 10 mM HEPES, 0.5 mM EGTA, 2 mM ATP, and 0.2 mM GTP (ATP and GTP were added immediately before use), pH adjusted to 7.4 using KOH). Initial pipette resistance was ϳ2 M⍀. Agonist/antagonists were delivered with an ultra-fast application system using a double barreled application pipette (the so-called -tube) controlled via a piezoceramic device (Burleigh Instruments) as described previously (16) . Data were sampled at 20 kHz, low-pass filtered at 6.7 kHz and only accepted if the series resistance was Ͻ10 M⍀. Series resistance was compensated by 80%. Agonist application pulses lasted 1 s and the stimulation frequency was 1 pulse per 30 s, to ensure full recovery of the nAChRs from agonist-induced desensitization between pulses. The responses of the patch clamp electrophysiological experiments were quantified by measuring peak current amplitude and relating this to 1 mM ACh control responses. Concentration-response curves were analyzed using GraphPad Prism. Figures displaying current traces were made using SigmaPlot.
X. laevis Oocyte Electrophysiology-Oocytes were subjected to two-electrode voltage-clamp electrophysiological testing using a custom-built system as described previously (19) . Drugs were dissolved in OR2 (90 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 , 5.0 mM HEPES, and pH adjusted to 7.5), and solutions were applied directly to the oocytes via a glass capillary tube placed in the vicinity of the cell to ensure rapid solution exchange (few seconds). Each application lasted ϳ1 min and peak current amplitudes were measured. To ensure full recovery between applications at high agonist concentrations, the protocol included dynamic adjustments of washing periods.
Homology Modeling and Induced-fit Docking-Homology models of the ␣3␤2, ␣3␤4, and ␣4␤4 dimer interfaces were built as previously described for our ␣4␤2 homology model (21) using the same template structures. The amino acid sequences of the other three subunit combinations were aligned to the templates by use of the alignment for the ␣4␤2 homology model and substitution of the ␣4 sequence with that of ␣3 and/or the ␤2 sequence with that of ␤4 using T-Coffee, version 9.01 (22) . The amino acid sequences of the LBDs of ␣3, ␣4, ␤2, and ␤4 (Protein Knowledgebase entries P32297, P43681, P17787, and P30926 from www.uniprot.org (23) (26) and energy minimized using MacroModel (27) with default settings. Both compounds were used as input for induced fit docking (28) in each of the four homology models using the centroid of (Ϫ)-nicotine included in the models to define the box center. Ligand and receptor van der Waals scaling was set to 0.8 and 1.0, respectively, maximum number of poses to 10, only the residues for which we previously altered conformations were optimized during refinement and otherwise default settings were used. The best scoring of each receptor-ligand combination according to IFDScore were selected for analysis.
RESULTS
Activation patterns of cytisine and the novel compound NS3861 ( Fig. 1 ) were investigated to address the relative contribution(s) to maximal agonist efficacy of the LBD and the TMD in heteromeric neuronal nAChRs. The compounds were tested at various combinations of wild-type subunits and subunit chimeras, which were generated by fusing the LBD of one subunit to the TMD of another subunit (denoted "LDB/TMD", i.e. ␣3/␣4, ␣4/␣3, ␤2/␤4, and ␤4/␤2). Because agonist properties are known to vary between heterologous expression systems (29) , it was chosen to address agonist efficacy using an ultra-fast solution exchange methodology in whole cell patch clamp analysis of receptors transiently expressed in the rat GH4C1 cell line.
Current densities for cells expressing chimeric subunits were, on average, less than for the comparable wild-type subunit combinations when the LBD contained ␣3, whereas receptors with ␣4 expressed well ( Table 1) . Lower expression levels of chimeric constructs versus wild-type can possibly reflect reduced efficiency of chimeric subunit assembly. However, in all the receptor combinations used here, current densities were more than sufficient to ensure reliable observations of partial agonists.
A prerequisite for using LBD/TMD chimeric constructs for evaluating agonist efficacy is conservation of basic biophysical properties such as expression level, kinetic properties, and agonist or antagonist sensitivity relative to wild-type receptor counterparts. To validate that the constructs used in this study adhere to this premise, two "fully" chimeric subunit combinations (␣3/␣4 ϩ ␤4/␤2 and ␣4/␣3 ϩ ␤2/␤4) were thoroughly evaluated initially and compared with wild-type heteromeric receptors.
Characterization of Wild-type and Chimeric nAChR Constructs-
The potency of ACh for activating wild-type ␣3␤4 and ␣4␤2 was in the range of ϳ80 M (Fig. 2) , which is comparable with previous studies (15, 30 -32) . This shows that the ␣4␤2 nAChRs predominantly assembled into the (␣4) 3 (␤2) 2 stoichiometry in these experiments (21) . Expression of the fully chimeric subunit combinations ␣4/␣3 ϩ ␤2/␤4 and ␣3/␣4 ϩ ␤4/␤2 yielded functional receptors with potencies of ACh in the same range as for the wild-type receptors (Fig. 2) , indicating normal responsiveness of chimeric receptors to ACh.
When evaluating efficacies of agonists at heteromeric nAChRs, a further complication relates to the fact that these can assemble in different stoichiometries of ␣-and ␤-subunits (30, 31, 33) . Because recent results have shown that acetylcholine and other agonists can activate an additional binding site in the ␣4␣4 interface (21), it is always necessary to consider whether agonists have stoichiometry dependent activation patterns.
ACh concentration-response relationships (CRR) for the fully chimeric and wild-type receptors were therefore evaluated in X. laevis oocytes. Under conditions favoring the 3␣:2␤ stoichiometry both wild-type and chimeric receptors with ␣4 in the LBD displayed ACh potencies in the same range as obtained in patch clamp, whereas conditions favoring 2␣:3␤ resulted in lower EC 50 values, in particular for ␣4␤2 (Table 2) . Receptors containing the ␣3-LBD in 3␣:2␤ stoichiometries appeared slightly (ϳ3-fold) less potent compared with the patch clamp experiments, but all data for wild-type receptors are in good agreement with previously reported results (15, 30 -32) .
Kinetic properties of ACh-activated currents at wild-type receptors containing the ␤2-subunit clearly displayed faster desensitization kinetics (Tau: ϳ50 ms) relative to those containing ␤4-subunits (Tau: ϳ250 ms) ( Fig. 3 and Table 1 ). A more slowly desensitizing/steady-state current, particularly in ␤2-containing receptors often followed initial rapid desensitization. These findings are in good support of earlier studies on nAChR kinetic properties (7, 34 -36) . With respect to desensi- 
TABLE 1 Time constants and current densities of wild-type and chimeric nAChRs
Patch clamp data were obtained as described in the legend to Fig. 2 . Time constants for current-decay of 1 mM ACh-evoked responses were calculated using a one-phase exponential decay nonlinear regression curve fitting routine. Data used for fitting were from the peak recorded value and 200 ms forward in time. The current densities are calculated as peak current of 1 mM ACh (pA) divided by the cell capacitance (pF) for n ϭ 10 experiments and values are presented Ϯ S.E.M.
Receptor
Tau Current density
tization kinetics for receptors containing chimeric subunits, all turned out to have desensitization time constants intermediate between those of wild-type receptors, except ␣3/␣4 ϩ ␤4 for which the value was slightly (ϳ2-fold) higher. Finally, conservation of basal pharmacological properties of the orthosteric site in the fully chimeric receptors was tested by determining the ability of the ␤2-selective competitive antagonist DH␤E to block wild-type and fully chimeric receptors. The amino acid determinants responsible for binding of DH␤E are known to be distributed across both ␣-and ␤-subunits (37-39). The potency of DH␤E for inhibition of ␣4␤2 exceeded that for inhibition of ␣3␤4 by more than 3 orders of magnitude (Fig. 2) . Replacing the TMD of ␣4␤2 with that of ␣3␤4 (i.e. ␣4/␣3 ϩ ␤2/␤4) did not affect high affinity DH␤E inhibition, whereas substitution of the LBD of ␣4␤2 with ␣3␤4 (i.e. ␣3/␣4 ϩ ␤4/␤2) reduced DH␤E potency to the level of the wild-type ␣3␤4 nAChR (Fig. 2) . This shows that the antagonist potency of DH␤E is fully defined by the LBD and that the structural integrity of the LBD is preserved in the chimeric receptors.
Based on these data, it is highly likely that all combinations of wild-type and chimeric constructs result in receptors, which express reliably in GH4C1 cells. Comparisons of ACh EC 50 values, desensitization time constants, and DH␤E IC 50 values for the fully chimeric receptors show that basic biophysical and ligand-binding properties were well preserved and generally match those of wild-type receptors.
Cytisine-Initially, cytisine was characterized with respect to its binding affinity for heteromeric nAChRs in radioligand displacement experiments, using membrane preparations from HEK293 cells stably expressing human ␣3␤2, ␣3␤4, ␣4␤2, or ␣4␤4 nAChRs. Cytisine was observed to displace [ 3 H]epibatidine from ␣4␤2 and ␣4␤4 nAChRs with subnanomolar affinity (Table 3) . Approximately 20-fold lower affinity was observed at the ␣3␤2 receptors and a further ϳ20-fold affinity reduction was seen at ␣3␤4 receptors.
Using patch clamp electrophysiology, the CRR of cytisine was subsequently determined at wild-type ␣3␤4 and ␣4␤2 nAChRs as well as fully chimeric receptors having the same LBD interfaces. Cytisine behaved as a low potency full agonist at the wild-type ␣3␤4 nAChR (Figs. 3B and 4) but produced no significant activation of the ␣4␤2 nAChR (E max Ͻ 10%) at concentrations up to 1 mM (Figs. 3I and 4) . At the fully chimeric receptors, cytisine had low efficacy at ␣3/␣4 ϩ ␤4/␤2 with potency roughly matching that at ␣3␤4 receptors (Figs. 3H and 4), whereas no appreciable efficacy was seen at ␣4/␣3 ϩ ␤2/␤4 receptors (Figs. 3O and 4) . Judging from the appearance of current traces for ␣3␤4 and ␣4␤4 (Fig. 3, B and J) , desensitization kinetics of cytisine resembled that of ACh. These results corroborate previous reports suggesting that cytisine binds potently to ␣4␤2 but primarily activates ␤4-containing receptors (7, 8, 15, 40) .
To further probe the importance of different LBD and TMD combinations, maximal efficacy of cytisine was determined at the remaining permutations of wild-type and chimeric constructs (Fig. 3, A, C-G, K-N, and P) . Combinations between any ␣-subunit (chimeric or wild-type) with wild-type ␤4 yielded high maximum cytisine efficacy (E max ϭ 76 -113%), whereas all combinations with a wild-type ␤2-subunit resulted in an almost complete loss (E max Ͻ 10%) of efficacy (Fig. 5A) . Replacing the TMD of ␤4 with that of ␤2 gave a substantial, but not complete, loss of efficacy (E max ϳ13-30% for ␣3, ␣4, ␣3/␣4, or ␣4/␣3 in combination with ␤4/␤2). On the other hand, irrespective of the ␣-subunit, replacing the TMD of ␤2 with that of ␤4 did not increase the efficacy levels above that observed for receptors containing the wild-type ␤2-subunit (E max Ͻ 10%). Finally, to investigate whether subunit stoichiometry of ␣4-containing receptors could affect the observed maximal efficacies of cytisine, CRRs were recorded on nAChRs expressed in oocytes (Table 2) . These experiments qualitatively confirm the subtype-selective efficacy of cytisine for ␤4-containing receptors observed from patch clamp studies in combinations with ␣4. Independent of the subunit ratio, cytisine did not activate ␣4␤2 receptors but activated ␣4␤4 receptors with submicromolar potencies (Table 2) .
NS3861-Characterization of NS3861 with respect to [
3 H]epibatidine displacement binding showed this compound to bind potently at all tested nAChR subtypes (Table 3) . NS3861 was ϳ10-fold affinity selective for ␣3␤4, relative to the ␣4␤4 nAChR and in both cases a ϳ10 -40-fold affinity reduction was observed by substituting ␤4 with ␤2. Thus, in sharp contrast to cytisine and nicotine, NS3861 has higher binding affinities at ␤4-versus ␤2-containing receptors.
By analogy to the experiments reported for cytisine, the CRR of NS3861 at ␣3␤2, ␣3␤4, and ␣4␤2, and two fully chimeric receptors was investigated using patch clamp electrophysiology. NS3861 was found to activate wild-type ␣3␤4 nAChRs (Figs. 3R and 4) but did not activate wild-type ␣4␤2 (Figs. 3Y  and 4) . Interestingly, whereas NS3861 was a partial agonist at ␣3␤4, it proved to be a full agonist at ␣3␤2 albeit with ϳ10-fold lower potency consistent with the binding affinities (Figs. 3Q  and 4 ). Efficacy at the ␣3/␣4 ϩ ␤4/␤2 receptor was almost identical to that of wild-type ␣3␤4 (Figs. 3X and 4) , whereas no efficacy could be seen at ␣4/␣3 ϩ ␤2/␤4 (Figs. 3AA and 4) . The activation and desensitization properties of currents evoked by NS3861 were generally reminiscent of the currents evoked by ACh, as judged from the appearance of current traces (Fig. 3, Q 
and R).
Maximal efficacy of NS3861 was next investigated in experiments involving the remaining permutations of wild-type and chimeric constructs (Fig. 3, S-W and Z) . Unlike the efficacy profile of cytisine, which was independent of the ␣-subunit, NS3861 was only capable of activating subunit combinations containing the LBD of ␣3, as no appreciable efficacy (E max Ͻ 10%) was detected in subunit combinations involving the LBD of ␣4 (Fig. 5B) . However, substituting wild-type ␣3 for the ␣3/␣4 chimera resulted in indistinguishable maximum efficacies. It is further evident, that in combination with an ␣3-LBD the identity of the ␤-subunit is highly important for efficacy. In these experiments, NS3861 acted as a full agonist whenever a ␤2-LBD was present (E max ϭ 97-129%), whereas it was only a partial agonist when a ␤4-LBD was present (E max ϭ 30 -55%). By analogy to the findings made for the ␣-subunit, the ␤-subunit influence on efficacy was also confined to the extracellular LBD.
The subtype-selective efficacy of NS3861 was qualitatively reproduced in oocytes ( Table 2 ). Independent of subunit ratios, NS3861 displayed no efficacy at ␣4␤2 receptors. ␣3␤2 and ␣3␤4 receptors expressed in 3␣:2␤ stoichiometries were, however, activated with maximal efficacies significantly above or partial relative to ACh, respectively. Because both combinations contain an ␣3␣3 interface the observed ␤2 subtype-selective efficacy appears independent of this interface.
Binding Modes of Cytisine and NS3861 in nAChR Homology Models-To obtain possible binding modes for cytisine and NS3861 the compounds were docked into homology models of ␣3␤2, ␣3␤4, ␣4␤2, and ␣4␤4 using an induced-fit protocol. Thus, side chain conformations of selected residues are sampled during the docking calculation with the ligand present in the binding site and different ligand-receptor complexes are given as output. The best scoring complexes of cytisine in each receptor model display the same binding mode matching the interactions of classical nicotinic agonists (5, 41) , with hydrogen bonds to the backbone carbonyl of a tryptophan and a water molecule (Fig. 6B) of ␤2; the only residues in the binding site that differ between the ␤2-and ␤4-subunits (Fig. 6A) . Contrary to cytisine, the obtained binding modes of NS3861 in all four homology models only display the hydrogen bond to the tryptophan and has the thiophene ring located perpendicular to the pyridine of, for example, nicotine (41) , with the bromine atom located near Phe 144 and Leu 142 of ␤2 and ␤4, respectively (Fig. 6C) . Furthermore, because of Thr 183 in ␣4 compared FIGURE 3. Representative traces of ACh-, cytisine-, and NS3861-evoked currents in patch-clamp experiments at the indicated nAChRs. Data were obtained as described in the legend to Fig. 2 and agonist application is shown as a solid bar above all current traces. The cytisine or NS3861 concentration giving rise to maximal efficacy at each receptor combination was identified by testing a range of concentrations. Traces shown are from compound concentrations that yielded maximal responses. Note that in many cases, the maximal response was not obtained with the highest concentration tested (see e.g. 100 M NS3861 at ␣3␤2 and 10 M NS3861 at ␣3␤4 in Fig. 4B ). There is no obvious technical reason for this but from previous similar observations it was speculated that it could be due to nonspecific ion-channel blockage at high ligand concentrations (46) . A-P, cytisine-evoked currents shown alongside 1 mM ACh-evoked currents recorded in the same cells. Cytisine concentrations were 100 M in traces F, J, L, N, and P, 316 M in trace B, and 1 mM in the remaining traces (from 5,000 to 100,000 times the highest observed binding K i value). Q-AA, NS3861-evoked currents shown alongside 1 mM ACh-evoked currents recorded in the same cells. NS3861 concentrations were 3.16 M in traces R and S, 10 M in traces Q, T, U, V, W, and X, and 100 M in the remaining traces (from 2,000 to 5,000 times the highest observed binding K i value). with Ser 181 in ␣3 the binding modes of NS3861 obtained in ␣4-containing receptors display a ϳ1 Å shift of the thiophene ring toward the ␤-subunit as measured on the sulfur and bromine atoms. This brings the bromine atom within 3.4 Å of one of the sulfur atoms in the disulfide bond of the C-loop and within 3.1 Å of one of the methyl groups of Leu 144/146 in the ␤-subunits (Fig. 6D) .
Agonistic Behavior of NS3861 and Cytisine on Point Mutated Receptors-To investigate if Ile
134 and Leu 142 of ␤4 were responsible for the selective cytisine activation of ␤4-versus ␤2-containing receptors, a mutant ␤2-subunit was constructed with two point mutations substituting the corresponding Val 136 and Phe 144 with Ile and Leu. Cytisine was then tested at ␣4␤2(V136I/F144L) receptors expressed in oocytes. Here it displayed clear agonistic behavior resulting in activation of the mutant receptor with an efficacy level (E max ϭ 18%; n ϭ 9; 95% confidence interval, 16 -19% ) comparable with what is observed for ␣4␤4 receptors in this system (Table 2) . Likewise, NS3861 was applied to ␣4(T183S)␤2 mutant receptors in oocytes to test if Thr 183 was responsible for the lack of activation of ␣4-containing receptors. Indeed, NS3861 activates the mutant receptor acting as a partial agonist (E max ϭ 36%; n ϭ 9; 95% confidence interval, 33-40%). Hence, the oocyte experiments qualitatively demonstrate the importance of Ile 134 and Leu 142 in ␤4 as well as Ser 181 in ␣3 for agonistic behavior of cytisine and NS3861, respectively.
DISCUSSION
Early studies have shown that both ␣-and ␤-subunits in nAChRs take part in defining the pharmacology of agonists at the macroscopic level (7, 8) . Recently, it was shown that at the microscopic level very specific agonist-receptor interactions at the complementary subunit determine efficacy of a series of compounds (14) . The present report extends this knowledge to functional studies of two agonists (cytisine and NS3861) with particularly pronounced profiles of efficacy selectivity (in the following the term "efficacy selectivity" is used to describe agonist subtype-selective efficacies). Furthermore, it was investigated whether efficacy is solely determined by the LBD or whether the TMD also plays a role.
Despite a high binding selectivity for ␤2-versus ␤4-containing nAChRs, our patch clamp data show that cytisine is a full agonist on ␤4-containing receptors and at best a very weak partial agonist when ␤2 is present, in line with previous reports FIGURE 4. CRRs for cytisine and NS3861 at wild-type and chimeric nAChRs. Patch clamp data were obtained as described in the legend to Fig. 2. A, cytisine is a full agonist at ␣3␤4 and a partial agonist at ␣3/␣4 ϩ ␤4/␤2 nAChRs (symbol identification as in panel C). Data points are plotted as mean Ϯ S.D. of n ϭ 3-11 experiments as a function of the cytisine concentration and fitted to the Hill equation by nonlinear regression. B, NS3861 is a full agonist at ␣3␤2 and a partial agonist at ␣3␤4 and ␣3/␣4 ϩ ␤4/␤2 nAChRs (symbol identification as in panel C). Data points are plotted as mean Ϯ S.D. of n ϭ 3-10 cells as a function of the NS3861 concentration and fitted to the Hill equation by nonlinear regression. The data points for 100 M NS3861 on ␣3␤2 and 10 M NS3861 on ␣3␤4 were omitted from the fitting routine as these concentrations yielded low submaximal responses. C, table of fitted maximal efficacy (E max ) and half-maximal activation concentration (EC 50 ) at the five receptor subtypes. Ϫ indicates E max Ͻ 10% set as minimum efficacy for reliable observations and fitting. EC 50 values for the two cytisine as well as the three NS3861 fitted graphs have overlapping 95% confidence intervals, respectively. FIGURE 5. Maximal efficacies of cytisine and NS3861 at wild-type and chimeric nAChRs. Patch clamp data for cytisine and NS3861 were obtained as described in the legends to Figs. 2-4 and maximal compound efficacy values are reported from the most efficacious concentrations as described in the legend to Fig. 3 . The horizontal dotted lines indicate the 10% level set as minimum for reliable efficacy detection. A, cytisine is a full agonist at receptors containing full-length ␤4-subunits, a partial agonist with ␤4/␤2-subunits, and has no efficacy at receptors containing a ␤2-LBD. B, NS3861 is a full agonist at receptors containing the LBD of ␣3␤2, a partial agonist with the LBD of ␣3/␤4, and has no efficacy at ␣4-containing receptors. Values are expressed as mean Ϯ S.D. of n ϭ 3-14 cells for each subunit combination. (7, 8, 15) . Furthermore, even though binding to ␣4␤4 occurs with ϳ250-fold higher affinity compared with ␣3␤4, the efficacy selectivity of cytisine is independent of the identity of the ␣-subunit. Importantly, cytisine displayed partial efficacy resulting in peak currents up to ϳ30% at receptors containing the ␤4/␤2-chimera clearly indicating a role of the TMD in determining maximal efficacy of this compound.
Maximal efficacy of agonists at ␣4␤2 receptors have previously been shown to be dependent on receptor stoichiometry (21) . However, concentration-response data obtained in oocytes expressing uniform populations of either (␣4) 3 (␤2) 2 or (␣4) 2 (␤2) 3 receptors lead to the conclusion that the presence of an ␣4␣4 interface has no or very limited effect on cytisine receptor activation (Table 2) .
In agreement with our previous observations on determinants of efficacy at nAChRs (14) , induced-fit docking of cytisine to homology models of the ␣4␤2 and ␣4␤4 interfaces suggests a larger van der Waals contact area and thus better interactions to the ␤4-versus ␤2-subunit as an explanation for the ␤4-selective activation. The only differences in the agonist binding site between ␤2-and ␤4-subunits are Val  136 and Phe  144 versus Ile   134 and Leu 142 , respectively (Fig. 6A) . The longer side chain of Ile versus Val and the nonplanar nature of Leu versus Phe allow a larger van der Waals contact surface between the complementary subunit and cytisine in ␤4-versus ␤2-containing receptors (Fig. 6B) . Because cytisine is relatively short compared with many other agonists, e.g. NS3861 and epibatidine, it may be imperative specifically for cytisine that the binding site residues of the complementary subunit are long, flexible and hydrophobic to make intimate van der Waals contacts and result in receptor activation. This hypothesis is supported by oocyte data in a receptor containing a mutant ␤2-subunit with Val 136 and Phe 144 point mutated to Ile and Leu, respectively. In this expression system, cytisine efficacy approaches the level observed for ␣4␤4 and although not comparable with the full activation observed in patch clamp, it is in sharp contrast to the lack of activation of wild-type ␣4␤2 in oocytes.
The novel nAChR agonist NS3861 presents a selectivity profile distinct from that of cytisine. Our patch clamp experiments show the nature of the ␣-subunit to be crucial for NS3861 activity. In addition, efficacy levels were determined by the nature of the ␤-subunit in a manner reciprocal to that of cytisine (i.e. ␤2 over ␤4). Full activation was seen at ␣3␤2 receptors, partial efficacy at ␣3␤4 receptors, and only insignificant peak currents at ␣4␤2 receptors. As NS3861 displays a binding affinity in the nanomolar range on ␣4␤2 receptors, the lack of activation at ␣4-containing receptors clearly does not reflect lack of binding. Furthermore, it is also independent of the presence of an ␣4␣4 interface. Irrespective of ␣-and ␤-subunit stoichiometry, NS3861 shows no efficacy at ␣4␤2 receptors and only marginal efficacy at ␣4␤4 receptors expressed in oocytes. Efficacy selectivity for ␣3␤2 versus ␣3␤4 was also qualitatively confirmed in oocytes under conditions where both populations contain an ␣3␣3 interface, which indicates that the maximal efficacy is independent of this interface. Additionally, contrary to cytisine the results from chimeric receptor combinations show that the efficacy of NS3861 was independent of TMD identity in these studies.
Structurally, the observed ␣3-selectivity of NS3861 might appear surprising as the only difference in the agonist binding site between the ␣3-and ␣4-subunit is Ser 181 versus Thr 183 , respectively (Fig. 6A) . However, in our obtained binding modes the orientation of the thiophene ring of NS3861 is almost perpendicular to the pyridine ring of, for example, NS3531 or nicotine in co-crystal structures with a homologous AChBP (14, 41) , presumably due to the presence of the bromo substituent. This puts the agonist under the influence of Thr 183 in ␣4 as evident by the ϳ1 Å shift in binding mode in ␣4␤2 compared with ␣3␤2 as measured on the thiophene sulfur and the bromine atoms (Fig. 6D) . Because the docking protocol used can only account for side chain flexibility, the full consequences in terms of backbone conformational changes in the receptor are uncertain. However, the shift in binding mode of NS3861, caused by Thr 183 of ␣4, brings the bromine within 3.4 Å of one of the sulfur atoms in the disulfide bond of the C-loop and within 3.1 Å of one of the methyl groups of Leu 146 and Leu 144 in the ␤2-and ␤4-subunits, respectively (Fig. 6D) . Such short distances correspond to steric clashes between agonist and receptor. This could indicate that the shifted binding mode of NS3861 in ␣4-containing receptors opposes channel activation by hindering a conformational change of the interface into the activated state, by preventing either a necessary agonist-mediated intimate contact between the ␣4-and the ␤-subunit and/or preventing full closure of the C-loop. This is backed by the observation that, whereas NS3861 was unable to activate wild-type ␣4␤2 receptors it displays agonistic behavior at ␣4(T183S)␤2 mutant receptors in oocytes. Although the obtained efficacy level in these experiments did not match that of wild-type ␣3␤2 it still demonstrates that Thr 183 is, at least partly, responsible for the lack of NS3861 efficacy on ␣4-containing receptors.
Consistent with the poor hydrogen bond acceptor ability of the thiophene sulfur atom we do not observe an interaction to the water molecule, as we do for cytisine (Fig. 6B) and, which has been reported for other agonists (12, 14, 41) . The fact that NS3861 is a full agonist at ␣3␤2 indicates that, in contrast to ␣4␤2 agonists (42), a hydrogen bond acceptor is not essential for full activation of ␣3␤2 receptors. This seems to be consistent with the situation in ␣7 nAChRs where a co-crystal structure of AChBP with an ␣7-selective agonist displays a binding mode, which does not involve interaction with the water molecule (12) . This is also consistent with superior binding affinity at ␣3-versus ␣4-containing receptors.
As was the case for cytisine, the ␤-subunit plays an important role for NS3861 efficacy but we observe almost the reverse ␤-subunit selectivity profile with preference for ␤2. To the best of our knowledge, NS3861 represents the first agonist reported to possess efficacy selectivity for the ␣3␤2 nAChR subtype. Based on the obtained binding modes at the ␣3␤2 and ␣3␤4 interfaces we do not observe a specific interaction as an obvious reason for the ␤2-efficacy selectivity of NS3861. Given that binding affinity at ␤2-containing receptors is ϳ10-fold lower than that at ␤4-containing receptors, this is perhaps not surprising. From the proximity of the bromine atom of NS3861 and Phe 144 of ␤2 (Fig. 6C) we propose an electrostatic interaction between the negative electrostatic potential around the circumference of the bromine and the positive electrostatic potential at the edge of the phenyl group in the phenylalanine (43) . Because polarization of aromatic rings is not explicitly handled in forcefield-based methods, such an interaction cannot be expected as part of the output from the induced-fit docking. However, our binding model of NS3861 in ␣3␤2 requires only a small conformational change of Phe 144 to establish this electrostatic interaction, which is not possible with Leu 142 in the ␤4-subunit and could be the reason for the selective activation.
The results obtained with cytisine and NS3861 corroborate previous reports that both the ␣-and ␤-subunits take part in determining the binding affinity in heteromeric receptors (3, 4) . The data are also consistent with previous observations that both subunits can affect agonist efficacy (7, 8) . However, by evaluating specific binding site determinants that make contacts to these agonists, a more detailed picture emerges. The data presented here for cytisine are perfectly consistent with a hypothesis stating that the ␣-subunit mostly plays a requisite role for agonist efficacy, in the sense that it provides a set of key determinants essential for agonist binding. Positioning of the positive charge of the ligand inside the aromatic nest delivered mostly by the ␣-subunit provides an excessive binding potential, which is necessary for high affinity binding, but not sufficient for gating. Ligand interactions with residues on the ␤-subunit are much weaker and thus play a less important role in agonist binding. However, because inter-subunit contacts are suggested to determine agonist efficacy (14) these weaker ␤-subunit interactions have a decisive role in fine-tuning agonist efficacy.
As illustrated by our homology models and binding modes derived from docking, both ␣3-and ␣4-subunits are capable of binding cytisine in a manner permissive for gating. However, despite a large difference in binding affinity, maximal efficacy ends up being fully determined by the ␤-subunit. Compared with other nicotine-like agonists, such as epibatidine and NS3920 (14) , cytisine is ϳ2 and ϳ3 Å shorter, respectively, measured from the cationic nitrogen to the most distal atom, and only the presence of Ile and Leu in ␤4 allows for sufficient van der Waals contact surface when it is docked in the model. Likewise, the ␣3-subunit is capable of binding NS3861 in a "correct" manner, but partial versus full agonism is determined by the ␤-subunit possibly through interactions with Phe 144 in ␤2. The fact that NS3861 does not activate ␣4-containing receptors may seem contradictory to the hypothesis of a requisite role for the ␣-subunit. However, the fact that Thr 183 in ␣4 prevents activation can be explained by the shift in NS3861 binding mode observed from our docking results, which may prevent NS3861 from binding in a manner permissive for gating. Thus, despite high affinity binding through the key ␣-determinants, no ␤-subunit can adapt sufficiently to give efficacy.
Recent publications have claimed that partial agonist efficacy is due to prevention of full C-loop closure (11) (12) (13) and thus originates from interactions with the principal component of the binding site, i.e. the ␣-subunit. Although the ␣3 efficacy selectivity of NS3861 could potentially also be explained by changes in C-loop closure, the remaining results obtained in this work are inconsistent with this hypothesis. Cytisine fully activates both ␣3␤4 and ␣4␤4 receptors but results in virtually no efficacy at ␣3␤2 and ␣4␤2 receptors (Fig. 5) . As seen, this can be rationalized by specific interactions between cytisine and residues from the ␤-subunit. In contrast, the C-loop closure hypothesis would imply that the specific combination of cytisine and ␤2 should prevent closure of the ␣3-and ␣4-C-loops. However, docking of cytisine to both ␣3␤2 and ␣4␤2 homology models show that in both cases a fully closed C-loop can accommodate this relatively small agonist without significant steric clashes. Furthermore, a very recent co-crystal structure of a AChBP with cytisine confirms our obtained binding mode and shows a fully closed C-loop (44) . In fact, two additional crystal structures of AChBPs in complex with partial agonists, lobeline (13) and varenicline (44) , also display full C-loop closure. Thus, the present data and the mentioned three AChBP crystal structures support the study by Rohde et al. (14) in which it is concluded that C-loop closure is not enough to explain differences in maximum efficacies and that agonist interactions with key binding site residues at the ␤-subunit plays a decisive role in controlling efficacy levels.
Another inference from the present data is that maximal efficacy can be affected by the nature of the ␤-subunit TMD. Although that may seem trivial, the influence is clearly highly agonist dependent. All the data obtained here were normalized to maximal ACh-evoked currents. Given that the maximal efficacy levels of NS3861 at receptors with the same ␣3-and ␤-LBD (e.g. ␣3␤2 and ␣3 ϩ ␤2/␤4) were virtually identical, maximal efficacy of ACh and NS3861 do not differ relative to each other. ACh and NS3861 thus have either identical or no ␤-subunit TMD dependence. Cytisine on the other hand clearly went from a full to a partial agonist when a wild-type ␤4-subunit was replaced with a ␤4/␤2-subunit. Although this underscores the importance of the ␤-subunit for determining efficacy it also suggests that ␤2-TMD containing receptors may be more difficult to gate and require particularly strong interactions to the complementary subunit, which cytisine may not be capable of even with a ␤4-LBD. The observations that ␤2-containing receptors generally desensitize more rapidly than ␤4-containing receptors is also consistent with such basic gating differences. No effects of LBD/TMD chimeras were seen for the ␣-subunits as long as the LBD remained constant, which in fact support the hypothesis of the requisite role of these subunits.
The gating mechanism of nAChRs is still not fully elucidated, but the data presented here points toward an important role of the ␤-subunit, which potentially involves global changes of ␤-subunit conformation. Such changes may be linked to the F-loop movement in the complementary subunit previously suggested as part of the activation mechanism (45) .
